Correspondence |

The Role of Narrowband UV-B Plus Alefacept Combination Therapy in the Treatment of Psoriasis

Heidi Jacobe, MD; Laura Winterfield, MD; Flora Kim, BS; Beverley Huet-Adams, MS; Rachael Cayce, BS
Arch Dermatol. 2008;144(8):1067-1068. doi:10.1001/archderm.144.8.1067.
Text Size: A A A
Published online


In the August 2007 issue of the Archives, Legat et al1 described the accelerated and improved clearance of psoriasis when alefacept is combined with narrowband (NB) UV-B phototherapy. Because all patients in this study were treated with alefacept and with a randomly selected body half exposed to NB UV-B phototherapy, the question remained as to whether the improvement seen was greater than what can be achieved with NB UV-B monotherapy. We present data from 16 patients with chronic plaque psoriasis requiring systemic or phototherapy who were enrolled in an institutional review board approved, randomized, double-blind, placebo-controlled study comparing alefacept with NB UV-B vs NB UV-B alone for the treatment of psoriasis.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure 1.

Reduction from baseline Psoriasis Area Severity Index (PASI) score during the 12-week treatment period and the 8-week posttreatment observation period. No statistical difference in PASI scores was found at 12 weeks using the 2-factor, repeated-measures analysis of variance model (P > .05). NB indicates narrowband.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Proportions of patients achieving Psoriasis Area Severity Index (PASI) scores of 50% or 75% by the end of the 12-week treatment period. NB indicates narrowband

Graphic Jump Location




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics